OMGA News and Press, Omega Therapeutics Inc. From 03/30/23

CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenetic mRNA medicines, today announced a clinical supply agreement with Roche ...

Omega Therapeutics press release ( NASDAQ: OMGA ): Q4 GAAP EPS of -$0.64 misses by $0.02 . Revenue of $0.73M (+421.4% Y/Y) beats by $0.47M . For further details see: Omega Therapeutics GAAP EPS of -$0.64 misses by $0.02, revenue of $0.73M beats by $0.47M

Advanced Company’s Lead Program, OTX-2002, in the Clinic; Preliminary Data from Phase 1/2 MYCHELANGELO™ I Trial Anticipated in 2023 Progressed IND-enabling Studies for OTX-2101; Company’s Development Candidate for MYC-driven Non-Small Cell Lung Cancer to Utilize...

Omega Therapeutics ( NASDAQ: OMGA ) chairman Noubar B. Afeyan buys $19.2M worth common stock of the company on February 27, 2023. He bought 3.3M shares, after which the company shares have climbed 10.6% . Noubar B. Afeyan, Ph.D. is the Chief Executive Officer, sole shareholder...

Omega Therapeutics ( NASDAQ: OMGA ) entered into a securities purchase agreement with investors for offering 6.9M shares at a purchase price of $5.78/share leading to gross proceeds of ~$40M. Offer is expected to close on Feb.27, 2023. For further details see: Omega...

CAMBRIDGE, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenetic mRNA medicines, today announced that it has entered into a securities pu...

CAMBRIDGE, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenetic mRNA medicines, today announced that it will present a trial-in-progress...

Omega Therapeutics ( NASDAQ: OMGA ) recovered from four days of consecutive declines on Thursday after H.C. Wainwright launched its coverage with a Buy recommendation noting that the clinical-stage biotech is a pioneer in epigenetic medicines. Omega's ( OMGA ) epigenomic programmi...

Omega Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference PR Newswire CAMBRIDGE, Mass. , Nov. 17, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the ...

Omega Therapeutics Named One of BioSpace's 2023 Best Places to Work PR Newswire CAMBRIDGE, Mass. , Nov. 15, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic appr...